Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Methoxyamphetamine (PMA) is a synthetic amphetamine derivative and designer drug with potent serotonergic activity. It acts primarily as a selective serotonin releasing agent (SSRA), increasing the release of serotonin from presynaptic neurons and inhibiting its reuptake. PMA also exhibits weak effects on dopamine and norepinephrine transporters compared to other amphetamines. Additionally, it is a potent reversible inhibitor of monoamine oxidase A (MAO-A), which can further elevate serotonin levels. The combination of these mechanisms contributes to its high toxicity profile and risk for life-threatening hyperthermia and other severe adverse effects at relatively low doses. PMA has no accepted medical use and is classified as a Schedule I controlled substance in the United States[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-Methoxyamphetamine.